Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

Blood (2025) 146 (Supplement 1): 586.

https://doi.org/10.1182/blood-2025-586

Published: 2025

Journal Articles

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Blood (2025) 146 (Supplement 1): 111.

https://doi.org/10.1182/blood-2025-111

Published: 2025

Journal Articles

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra, Edmund Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, Scott Killian, J. Scott McClellan, Nate Fernhoff, Robert Lowsky

Blood (2025) 146 (Supplement 1): 932.

https://doi.org/10.1182/blood-2025-932

Published: 2025

Journal Articles

Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T)

Arpita Gandhi, Anna Purdum, Anna Pavlova, Ai Li, J. Scott McClellan, Bronwen Shaw, Rachel Cusatis

Blood (2025) 146 (Supplement 1): 2473.

https://doi.org/10.1182/blood-2025-2473

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood (2025) 145 (18): 2012–2024.

https://doi.org/10.1182/blood.2024026446

Published: 2025

Includes: Supplemental data

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Claudia Djambas Khayat, Robert F Sidonio, Jr., Anna Pavlova

Blood (2023) 142 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2023-180585

Published: 2023

Journal Articles

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Samer A. Srour, Amandeep Salhotra, Robert Lowsky, Rasmus T. Hoeg, Edmund K. Waller, Anna Pavlova, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Mehrdad Abedi

Blood (2023) 142 (Supplement 1): 773.

https://doi.org/10.1182/blood-2023-189534

Published: 2023

Journal Articles

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, Rasmus T. Hoeg, Sagar S. Patel, Edmund K. Waller, Jeremy M. Pantin, Caspian H. Oliai, J. Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2023-188994

Published: 2023

Journal Articles

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Blood (2023) 142 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2023-188162

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Novel Gamma-Glutamyl Carboxylase Mutation Causing Hemorrhagic and Non-Hemorrhagic VKCFD1 Phenotypes

Gianna M. Guzzardo, Suvoshree Ghosh, Behnaz Pezeshkpoor, Anna Pavlova, Katrin Czogalla-Nitsche, Johannes Oldenburg, Meera B. Chitlur

Blood (2022) 140 (Supplement 1): 8480–8482.

https://doi.org/10.1182/blood-2022-169105

Published: 2022

Journal Articles

Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Everett H Meyer, M Scott Killian, Anna Pavlova, Cameron Bader, Sean Summers, Fernando Teque, J Scott McClellan, Nathaniel B Fernhoff

Blood (2022) 140 (Supplement 1): 7656–7657.

https://doi.org/10.1182/blood-2022-164468

Published: 2022

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Amandeep Salhotra, Samer A Srour, Rasmus T Hoeg, Ayman Saad, Everett H Meyer, Anna Pavlova, Edmund K. Waller, Mwe Mwe Chao, J Scott McClellan, Nathaniel B Fernhoff, Robert Lowsky, Mehrdad Abedi

Blood (2022) 140 (Supplement 1): 1865–1866.

https://doi.org/10.1182/blood-2022-170459

Published: 2022

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T)

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Immunogenicity of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate during the Wil-31 Prophylaxis Study in Patients with Von Willebrand Disease

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Novel Gamma-Glutamyl Carboxylase Mutation Causing Hemorrhagic and Non-Hemorrhagic VKCFD1 Phenotypes

Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only